|
Number of patients
|
111
| | |
|
Age (yrs)
|
42.2 ± 10.3
| | |
|
Gender (male) (n, %)
|
78 (70)
| | |
|
Duration of symptoms (yrs)
|
16 (1 to 49)
| | |
|
Time since diagnosis (yrs)
|
9 (0 to 37)
| | |
|
HLA-B27+ (n, %)
|
88 (81)
| | |
|
History of IBD (n, %)
|
11 (10)
| | |
|
History of uveitis (n, %)
|
31 (28)
| | |
|
History of psoriasis (n, %)
|
9 (8)
| | |
|
Peripheral arthritis (n, %)
|
21 (19)
| | |
|
Current NSAID use (n, %)
|
98 (88)
| | |
|
Current DMARD use (n, %)
|
26 (23)
| | |
|
BASDAI (range 0 to 10)
|
6.1 ± 1.7
|
BASDAI ≥ 4 (n, %)
|
98 (88)
|
|
ASDASCRP
|
3.8 ± 0.8
|
ASDASCRP ≥ 2.1 (n, %)
|
105 (96)
|
|
Physician's GDA (range 0 to 10)
|
5 (1 to 9)
| | |
|
Patient's GDA (range 0 to 10)
|
7 (1 to 10)
| | |
|
ESR (mm/h)
|
22 (2 to 90)
|
Increased ESR (n, %)
|
86 (78)
|
|
CRP (mg/l)
|
15 (2 to 99)
|
Increased CRP (n, %)
|
84 (76)
|
|
BASFI (range 0 to 10)
|
6.1 ± 2.0
| | |
|
Chest expansion (cm)
|
3.0 (0.5 to 10.0)
| | |
|
Modified Schober test (cm)
|
2.9 (0.1 to 7.0)
| | |
|
Occiput to wall distance (cm)
|
5.0 (0.0 to 28.0)
| | |
|
Lateral lumbar flexion L (cm)
|
8.7 ± 4.1
| | |
|
Lateral lumbar flexion R (cm)
|
8.4 ± 4.3
| | |
|
ASQoL (range 0 to 18)
|
10 ± 4
| | |
|
BALP (U/L)
|
17.2 (1.6 to 36.5)
| | |
|
BALP Z-score
|
0.28 (-2.59 to 5.16)
| | |
|
PINP (μg/l)
|
45.6 (16.0 to 98.0)
| | |
|
PINP Z-score
|
0.35 (-1.75 to 3.63)
| | |
|
sCTX (pg/ml)
|
206.0 (13.4-657.1)
| | |
|
sCTX Z-score
|
-0.34 (-2.58 to 4.01)
| | |
|
LS BMD T-score
|
-0.58 ± 1.41
|
Osteopenia LS (n, %)
|
34 (34)
|
| | |
Osteoporosis LS (n, %)
|
9 (9)
|
|
LS BMD Z-score
| |
LS Z-score ≤ -2.0 (n, %)
|
9 (9)
|
|
Hip BMD T-score
|
-0.53 ± 1.12
|
Osteopenia hip (n, %)
|
38 (37)
|
| | |
Osteoporosis hip (n, %)
|
2 (2)
|
|
Hip BMD Z-score
| |
Hip Z-score ≤ -2.0 (n, %)
|
4 (4)
|
